Abstract:Background & Aims Remodeling the tumor microenvironment is a critical strategy for treating advanced hepatocellular carcinoma (HCC). Yet it remains poorly understood how distinct cell populations in the microenvironment mediate tumor resistance to immunotherapy such as anti-PD-1. Methods We analyzed the transcriptomic profiling at a single-cell resolution within tumor tissues from HCC patients scheduled to receive anti-PD-1-based immunotherapy. Our comparative analysis and experimental validation using flow cytometry and histopathological analysis uncovered a discrete subpopulation of cells associated with resistance to anti-PD-1 treatment in HCC patients and a rat model. A TurboID-based proximity labeling approach was deployed to gain mechanistic insights into the reprogramming of the HCC microenvironment. Results Here, we found specifically CD10 + ALPL + NEUs to be associated with resistance to anti-PD-1 treatment. These NEUs exhibited a strong immunosuppressive activity of inducing an apparent "irreversible" exhaustion of T cells in terms of cell number, frequency, and gene profile. Mechanistically, specifically CD10 + ALPL + NEUs were induced by tumor cells, i.e. , tumor-secreted NAMPT reprogrammed CD10 + ALPL + NEUs through NTRK1, maintaining the immature state and inhibiting the maturation and activation of CD10 + ALPL + NEUs. Conclusions Collectively, our results revealed a fundamental mechanism involving CD10 + ALPL + NEUs for tumor immune escape from durable anti-PD-1 treatment and provided further insights into immunotherapy targets or anti-PD-1 synergistic treatment regimens. Impact and implications Herein, we discovered that tumor cells reprogrammed CD10 + ALPL + NEUs to induce the "irreversible" exhaustion of T cells and hence allow the tumors to escape from the intended effects of anti-PD-1 treatment. Our data provided a new theoretical basis for the elucidation of special cell populations and a molecular mechanism underpinning resistance to immunotherapy. Targeting these cells contributed to evaluating indications for immunotherapy and could be looked at as a potentially more effective therapeutic approach.

Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC ​by mediating irreversible exhaustion of T cells

Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells